查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701397

罕見疾病基因檢測市場規模、佔有率、趨勢分析報告：按疾病、技術、專業、最終用途、地區、細分市場預測，2025-2030 年

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease, By Technology, By Specialty, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

罕見疾病基因檢測市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球罕見疾病基因檢測市場規模預計到2030年將達到25.2億美元，2025年至2030年的複合年成長率為15.3%。

有效的應對罕見疾病的監管計劃是該行業的主要驅動力之一。此外，許多提供相關疾病數據和資訊的登記機構的存在也促進了過去幾年收益的成長。持續舉辦會議以提高人們對罕見和極罕見疾病的認知，預計將促進診斷試劑套件和服務的採用。例如，在英國、德國、荷蘭和波蘭設有辦事處的 Ergomed 和 PSR Orphan Experts 參與了旨在提高該領域認知的各種活動。

此外，加拿大罕見疾病組織 (CORD) 為簡化衛生政策和專注於管理患有罕見疾病患者的衛生系統提供了強大的平台。該研究所與臨床醫生、研究人員、政府和診斷產業合作，推動國內所有罕見疾病的研發、診斷、治療和服務提供。根據美國衛生研究院 (NIH) 的數據，大約有 3000 萬美國人被確診患有 7000 多種已知的罕見疾病之一。隨著人們認知的提高，預計未來幾年接受該疾病檢測的患者數量將會增加。在美國，慶祝罕見疾病日是為了提高人們的認知並鼓勵該領域的發展。

此外，罕見疾病臨床研究網路 (RDCRN) 是一個由 NIH 資助的研究網路，由 23 個活躍的聯盟和研究小組組成，致力於讓患者、研究人員和臨床醫生專注於疾病的診斷和治療。在 COVID-19 疫情期間，未確診罕見疾病患者面臨重大健康挑戰。根據美國研究小組於2021年1月發表的一項研究，迫切需要開發能夠緩解罕見和未確診疾病（RUD）患者及其家人所面臨的嚴重挑戰的方法。這些挑戰包括診斷和預後的不確定性，加上醫療保健的複雜性，導致更差的健康結果。

病患權益團體和專業社群已加強應對疫情帶來的挑戰。例如，稀有染色體支持小組 (UNIQUE)、英國基因組醫學學會和英國遺傳聯盟等組織積極參與支持、倡導和告知患有這種疾病的患者。一些罕見疾病仍未分類。慈善機構 SWAN UK 估計，英國每年約有 6,000 名嬰兒出生時患有這種遺傳疾病。因此，無法做出適當的診斷或預測實證治療的預後。目前，英國接受基因檢測的兒童中約有 50% 未能明確的診斷。

大約 50% 患有學習障礙的兒童和 60% 患有先天性疾病的兒童無法得到明確的診斷以確定其殘疾的原因。此外，患者和家屬對診斷和基因檢測缺乏認知，進一步阻礙了該行業的發展。由於罕見疾病發病率高、註冊數量高、該領域擁有大量研發設施以及在診斷方面投入大量資金，北美在 2021 年佔據了該行業的主導地位。由於有大量專注於疾病管理的組織，預計亞太地區在預測期內的複合年成長率將最快。

罕見疾病基因檢測市場報告重點

  • 預計免疫學領域將在 2024 年佔據 12.56% 的最大佔有率，並有望在預測期內延續這一趨勢。
  • 2024 年，次世代定序領域佔最大佔有率，為 35.50%。基於 NGS 的癌症、神經系統疾病、心血管疾病、兒科疾病、精神疾病和其他罕見疾病的基因組的廣泛普及和採用，極大地推動了這一領域的發展。
  • 根據專業性，分子遺傳檢測領域將在 2024 年佔據最大的收益佔有率，為 41.12%，預計在預測期內將以最快的複合年成長率保持其主導地位。
  • 根據最終用途，由於與基因檢測公司的合作和夥伴關係不斷增加，診斷檢測部門預計在研究期間的複合年成長率為 17.36%。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 罕見疾病基因檢測市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 罕見疾病基因檢測市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 定價分析

第4章 罕見疾病基因檢測市場：疾病預測與趨勢分析

  • 全球罕見疾病基因檢測市場：疾病儀表板
  • 全球罕見疾病基因檢測市場：疾病趨勢分析
  • 全球罕見疾病基因檢測市場收益（依疾病類型）
  • 神經系統疾病
  • 免疫系統疾病
  • 血液系統疾病
  • 內分泌和代謝紊亂
  • 癌症
  • 肌肉骨骼疾病
  • 心血管疾病
  • 皮膚病
  • 其他罕見疾病

第5章 罕見疾病基因檢測市場：依技術分類的估價與趨勢分析

  • 全球罕見疾病基因檢測市場：技術儀表板
  • 全球罕見疾病基因檢測市場：技術趨勢分析
  • 全球罕見疾病基因檢測市場收益（按技術）
  • 次世代定序（NGS）
    • 全EXOME定序
    • 全基因組序列分析
  • 陣列技術
  • 魚
  • 桑格定序
  • 核型分析

第6章：罕見疾病基因檢測市場：依專業領域估計與趨勢分析

  • 全球罕見疾病基因檢測市場：專業儀表板
  • 全球罕見疾病基因檢測市場：各專業的差異分析
  • 全球罕見疾病基因檢測市場按專業分類的收益
  • 分子遺傳學檢測
  • 染色體基因檢測
  • 生化基因檢測

7. 罕見疾病基因檢測市場：按疾病、技術、專業、最終用途和調查方法的區域估計和趨勢分析

  • 區域儀表板
  • 市場規模：預測趨勢分析：2018 年至 2030 年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Quest Diagnostics Inc.
    • Centogene NV
    • Invitae Corp.
    • F. Hoffmann-La Roche Ltd
    • Arup Laboratories
    • Eurofins Scientific
    • Strand Life Sciences
    • Ambry Genetics
    • Perkin Elmer;Inc.
    • Realm IDX;Inc.
Product Code: GVR-4-68038-695-0

Rare Disease Genetic Testing Market Growth & Trends:

The global rare disease genetic testing market size is estimated to reach USD 2.52 billion by 2030, registering a CAGR of 15.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Effective regulatory plans to combat rare disease is one of the key drivers of the industry. Furthermore, the presence of a substantial number of registries that provide data and relevant information about related diseases has aided in revenue growth over the past years. Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services. For instance, Ergomed and PSR Orphan Experts, with their offices in the U.K., Germany, the Netherlands, Poland, and other countries, participate in various activities that are aimed at raising awareness in this area.

Moreover, the Canadian Organization for Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that is dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments, and the diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. The number of patients undergoing disease testing is expected to increase in the coming years with growing awareness. The U.S. celebrates Rare Disease Day and promotes developments in this area by raising awareness.

In addition, the presence of the Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active consortia or research groups that includes patients, researchers, and clinicians who are focused on the diagnosis & treatment of disorders is anticipated to positively impact the industry. Amidst the COVID-19 pandemic, patients with undiagnosed and rare diseases have been facing significant health challenges. According to a study published in January 2021 by a group of researchers from the U.S., there is an urgent need for the development of approaches that can reduce the serious challenges affecting Rare & Undiagnosed diseases (RUD) patients and families. The challenges include diagnostic and/or prognostic uncertainty coupled with medical complexity leading to poor health outcomes.

In response to the challenges created by the pandemic, patient support groups and professional societies are actively involved in addressing these challenges. For instance, the Rare Chromosome Support Group (Unique), the British Society for Genomic Medicine, and Genetic Alliance U.K. are actively involved in supporting, advocating, and providing information to patients with diseases. Several rare conditions remain unclassified. The charity SWAN U.K. estimated that around 6,000 children are born each year with genetic conditions in the U.K. As per the agency, the conditions are extremely rare and cannot be named. Thus, there is a lack of proper diagnosis and prognosis for evidence-based treatment. At present, around 50% of the children who undergo genetic testing in the U.K. would not receive a confirmed diagnosis.

Around 50% of the children with learning disabilities and approximately 60% of children with congenital conditions do not receive a definitive diagnosis to identify the cause of their disabilities. Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth. North America dominated the industry in 2021 due to the high incidence of rare diseases, a large number of registries, the presence of substantial numbers of R&D facilities in this area, and extensive investments in diagnosis. Asia Pacific is expected to register the fastest CAGR during the forecast years owing to the presence of a substantial number of organizations that are focusing on disease management.

Rare Disease Genetic Testing Market Report Highlights:

  • The immunological disorders segment held the largest share of 12.56% in 2024 and is expected to continue the trend during the forecast period.
  • The Next Generation Sequencing segment held the largest share of 35.50% in 2024. The wide availability and adoption of NGS-based gene panels for cancer, neurological diseases, cardiovascular diseases, pediatric conditions, psychiatric disorders, and other rare diseases have significantly driven the segment.
  • Based on specialty, the molecular genetic tests segment accounted for the largest revenue share of 41.12% in 2024 and expected to maintain its dominant position with fastest CAGR during the forecast period.
  • On the basis of end-use, the diagnostic laboratories segment is expected to register the fastest CAGR of 17.36% over the study period, driven by rising number of partnership and collaboration activities of diagnostic laboratories with genetic testing companies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Technology
    • 1.2.3. Specialty
    • 1.2.4. End use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease
    • 2.2.2. Technology
    • 2.2.3. Specialty
    • 2.2.4. End use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rare Disease Genetic Testing Market Variables; Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Expanding patient registry for rare disease
      • 3.2.1.2. Declining sequencing cost
      • 3.2.1.3. Technological advancements in disease diagnosis
      • 3.2.1.4. Launch of programs & new product development in rare disease diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Absence of effective diagnosis framework
      • 3.2.2.2. Technical challenges associated with genetic tests & data management
  • 3.3. Rare Disease Genetic Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Rare Disease Genetic Testing Market: Disease Estimates & Trend Analysis

  • 4.1. Global Rare Disease Genetic Testing Market: Disease Dashboard
  • 4.2. Global Rare Disease Genetic Testing Market: Disease Movement Analysis
  • 4.3. Global Rare Disease Genetic Testing Market by Disease; Revenue
  • 4.4. Neurological Disorders
    • 4.4.1. Neurological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Immunological Disorders
    • 4.5.1. Immunological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Hematology Diseases
    • 4.6.1. Hematology Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Endocrine & Metabolism Diseases
    • 4.7.1. Endocrine & Metabolism Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Cancer
    • 4.8.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Musculoskeletal Disorders
    • 4.9.1. Musculoskeletal Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Cardiovascular Disorders
    • 4.10.1. Cardiovascular Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Dermatology Diseases
    • 4.11.1. Dermatology Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Other Rare Diseases
    • 4.12.1. Other Rare Diseases market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rare Disease Genetic Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Global Rare Disease Genetic Testing Market: Technology Dashboard
  • 5.2. Global Rare Disease Genetic Testing Market: Technology Movement Analysis
  • 5.3. Global Rare Disease Genetic Testing Market by Technology; Revenue
  • 5.4. Next-Generation Sequencing (NGS)
    • 5.4.1. Next-Generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Whole Exome Sequencing
      • 5.4.2.1. Whole Exome Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Whole Genome Sequencing
      • 5.4.3.1. Whole Genome Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Array Technology
    • 5.5.1. Array Technology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. FISH
    • 5.6.1. FISH market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Sanger Sequencing
    • 5.7.1. Sanger Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Karyotyping
    • 5.8.1. Karyotyping market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare Disease Genetic Testing Market: Specialty Estimates & Trend Analysis

  • 6.1. Global Rare Disease Genetic Testing Market: Specialty Dashboard
  • 6.2. Global Rare Disease Genetic Testing Market: Specialty Movement Analysis
  • 6.3. Global Rare Disease Genetic Testing Market by Specialty; Revenue
  • 6.4. Molecular Genetic Tests
    • 6.4.1. Molecular Genetic Tests market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Chromosomal Genetic Tests
    • 6.5.1. Chromosomal Genetic Tests market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Biochemical Genetic Tests
    • 6.6.1. Biochemical Genetic Tests market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rare Disease Genetic Testing Market: Regional Estimates & Trend Analysis by Disease; Technology; Specialty; End use and Methodology

  • 7.1. Regional Dashboard
  • 7.2. Market Size; & Forecasts Trend Analysis; 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis; By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis; 2024
    • 8.3.4. Quest Diagnostics Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Centogene N.V.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Invitae Corp.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffmann-La Roche Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Arup Laboratories
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Eurofins Scientific
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Strand Life Sciences
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Ambry Genetics
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Perkin Elmer; Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Realm IDX; Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Rare diseases genetic testing market; by region; 2018 - 2030 (USD Million)
  • Table 3 North America Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 4 North America Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 5 North America Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 6 North America Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 7 U.S Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 8 U.S Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 9 U.S Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 10 U.S Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 11 Canada Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 12 Canada Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 13 Canada Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 14 Canada Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 15 Mexico Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 16 Mexico Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 17 Mexico Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 18 Mexico Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 19 Europe Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 20 Europe Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 21 Europe Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 22 Europe Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 23 UK Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 24 UK Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 25 UK Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 26 UK Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 27 Germany Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 28 Germany Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 29 Germany Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 30 Germany Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 31 France Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 32 France Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 33 France Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 34 France Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 35 Italy Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 36 Italy Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 37 Italy Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 38 Italy Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 39 Spain Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 40 Spain Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 41 Spain Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 42 Spain Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 43 Denmark Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 44 Denmark Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 45 Denmark Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 46 Denmark Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 47 Sweden Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 48 Sweden Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 49 Sweden Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 50 Sweden Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 51 Norway Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 52 Norway Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 53 Norway Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 54 Norway Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 59 Japan Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 60 Japan Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 61 Japan Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 62 Japan Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 63 China Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 64 China Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 65 China Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 66 China Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 67 India Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 68 India Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 69 India Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 70 India Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 71 Australia Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 72 Australia Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 73 Australia Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 74 Australia Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 75 South Korea Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 76 South Korea Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 77 South Korea Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 78 South Korea Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 79 Thailand Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 80 Thailand Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 81 Thailand Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 82 Thailand Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 83 Latin America Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 84 Latin America Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 85 Latin America Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 86 Latin America Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 87 Brazil Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 88 Brazil Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 89 Brazil Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 90 Brazil Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 91 Argentina Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 92 Argentina Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 93 Argentina Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 94 Argentina Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 95 MEA Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 96 MEA Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 97 MEA Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 98 MEA Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 99 South Africa Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 100 South Africa Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 101 South Africa Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 102 South Africa Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 107 UAE Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 108 UAE Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 109 UAE Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 110 UAE Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)
  • Table 111 Kuwait Rare diseases genetic testing market; by disease; 2018 - 2030 (USD Million)
  • Table 112 Kuwait Rare diseases genetic testing market; by technology; 2018 - 2030 (USD Million)
  • Table 113 Kuwait Rare diseases genetic testing market; by specialty; 2018 - 2030 (USD Million)
  • Table 114 Kuwait Rare diseases genetic testing market; by end use; 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Rare Disease Genetic Testing market: market outlook
  • Fig. 14 Rare Disease Genetic Testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Rare Disease Genetic Testing market driver impact
  • Fig. 18 Rare Disease Genetic Testing market restraint impact
  • Fig. 19 Rare Disease Genetic Testing market: Disease movement analysis
  • Fig. 20 Rare Disease Genetic Testing market: Disease outlook and key takeaways
  • Fig. 21 Neurological Disorders market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 22 Hematology Diseases market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 23 Endocrine & Metabolism Diseases market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 24 Cancer market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 25 Musculoskeletal Disorders market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 26 Cardiovascular Disorders market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 27 Dermatology Diseases market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 28 Other Rare Diseases market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 29 Rare Disease Genetic Testing market: Technology movement analysis
  • Fig. 30 Rare Disease Genetic Testing market: Technology outlook and key takeaways
  • Fig. 31 Next-Generation Sequencing (NGS) market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 32 Whole Exome Sequencing market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 33 Whole Genome Sequencing market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 34 Rare Disease Genetic Testing market: Specialty movement analysis
  • Fig. 35 Rare Disease Genetic Testing market: Specialty outlook and key takeaways
  • Fig. 36 Molecular Genetic Tests market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 37 Chromosomal Genetic Tests market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 38 Biochemical Genetic Tests market estimates and forecast; 2018 - 2030 (USD Million)
  • Fig. 39 Global Rare Disease Genetic Testing market: Regional movement analysis
  • Fig. 40 Global Rare Disease Genetic Testing market: Regional outlook and key takeaways
  • Fig. 41 Global Rare Disease Genetic Testing market share and leading players
  • Fig. 42 North America; by country
  • Fig. 43 North America market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts; 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players - Rare Disease Genetic Testing market